The management of Eisenmenger syndrome in the modern treatment era: A case report

European Respiratory Review

Volumn 20, Issue 122, 2011, Pages 293-301

  Gatzoulis, M A ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; SILDENAFIL;

6 MINUTE WALK DISTANCE; ADULT; ANKLE EDEMA; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG TOLERABILITY; EISENMENGER COMPLEX; FEMALE; FUNCTIONAL STATUS; HEART INDEX; HEART LEFT RIGHT SHUNT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; IRON DEFICIENCY ANEMIA; LETTER; LUNG BLOOD FLOW; MONOTHERAPY; OUTCOME ASSESSMENT; OXYGEN SATURATION; PREGNANCY TERMINATION; PULMONARY HYPERTENSION; QUALITY OF LIFE; TRANSIENT ISCHEMIC ATTACK;

ADULT; ANTIHYPERTENSIVE AGENTS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; EISENMENGER COMPLEX; EXERCISE TOLERANCE; FEMALE; HEART SEPTAL DEFECTS, VENTRICULAR; HUMANS; HYPERTENSION, PULMONARY; IRON, DIETARY; PIPERAZINES; PURINES; QUALITY OF LIFE; SULFONAMIDES; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 82555183015     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00006211     Document Type: Letter

References (38)

1. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007; 115: 1039-1050.
2. Gatzoulis MA, Alonso-Gonzalez R, Beghetti M. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur Respir Rev 2009; 18: 154-161.
3. Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31: 2915-2957.
4. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
5. Hoetzenecker K, Ankersmit HJ, Bonderman D, et al. Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: a case report. J Thorac Cardiovasc Surg 2009; 137: 760-761.
6. Kim YH, Yu JJ, Yun TJ, et al. Repair of atrial septal defect with Eisenmenger syndrome after long-term sildenafil therapy. Ann Thorac Surg 2010; 89: 1629-1630.
7. Frost AE, Quiñones MA, Zoghbi WA, et al. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005; 24: 501-503.
8. Hirabayashi A, Miyaji K, Akagi T. Continuous epoprostenol therapy and septal defect closure in a patient with severe pulmonary hypertension. Catheter Cardiovasc Interv 2009; 73: 688-691.
9. Schwerzmann M, Zafar M, McLaughlin PR, et al. Atrial septal defect closure in a patient with irreversible pulmonary hypertensive arteriopathy. Int J Cardiol 2006; 110: 104-107.
10. Galié N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
11. Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009; 30: 256-265.
12. Stoica SC, McNeil KD, Perreas K, et al. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results. Ann Thorac Surg 2001; 72: 1887-1891.
13. Waddell TK, Bennett L, Kennedy R, et al. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002; 21: 731-737.
14. Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132-143.
15. Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease. Circulation 1993; 87: 1954-1959.
16. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996; 28: 768-772.
17. Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006; 27: 1737-1742.
18. Broberg CS, Bax BE, Okonko DO, et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol 2006; 48: 356-365.
19. Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-topulmonary shunts and Eisenmenger's syndrome. Drugs 2008; 68: 1049-1066.
20. Tay EL, Peset A, Papaphylactou M, et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol 2011; 151: 307-312.
21. Kermeen FD, Franks C, O'Brien K, et al. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21. Heart Lung Circ 2010; 19: 595-600.
22. Berger RM, Beghetti M, Galié N, et al. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. Int J Cardiol 2010; 144: 373-378.
23. Duffels MG, van der Plas MN, Surie S, et al. Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism. Neth Heart J 2009; 17: 334-338.
24. Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 2007; 93: 974-976.
25. Hopkins WE, Ochoa LL, Richardson GW, et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15: 100-105.
26. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.
27. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691-694.
28. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863.
29. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-1010.
30. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-1922.
31. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263.
32. Simonneau G, Rubin LJ, Galié N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.
33. D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2010; [Epub ahead of print DOI: 10.1016/j.ijcard. 2010.10.051].
34. Bendayan D, Shitrit D, Kramer MR. Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. Respirology 2008; 13: 916-918.
35. Post MC, Janssens S, Van de Werf F, et al. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J 2004; 25: 1651-1656.
36. D'alto M, Romeo E, Argiento P, et al. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. Heart 2010; 96: 1475-1479.
37. Galié N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
38. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121: 20-25.